Press

Cancer Immunotherapy Biomarkers: Four Trends to Watch

  • Using state of the art technologies for biomarker development
  • Validating PD-L1 as a biomarker of response
  • Linking tumor mutation burden to response rate
  • Leveraging the tumor microenvironment to direct therapeutic development

Considering Genomic Research?
*
 
*
*
 


2019 © MedGenome • All Rights Reserved